You lost weight steadily, then the scale parked itself at the same number for three months. Before you decide the medication "stopped working," it's worth understanding what your body actually does during a long cut — because the slowdown you're feeling may be physiology, not failure.

The plateau isn't always what it looks like

If you're a former athlete, you already know your body adapts to load. The same thing happens with energy balance. When you sustain a calorie deficit, your body defends its fat stores by quietly reducing how much energy it burns — a phenomenon researchers call adaptive thermogenesis or metabolic adaptation. Studies tracking people through significant weight loss have measured a drop in resting energy expenditure that is larger than what you'd predict from lost body mass alone, and it can persist for years [1][2].

In plain terms: the engine downshifts. A smaller, lighter body needs fewer calories, and on top of that, the body becomes *more efficient* at running on less. That's not the drug quitting. It's the same regulatory system that made it hard to keep weight off long before GLP-1 medications existed.

GLP-1 and dual GIP/GLP-1 agonists work largely on appetite and satiety signaling, helping reduce energy intake [3]. But they don't switch off the body's defense of its set point. So when intake creeps back up — even slightly — at the same time expenditure drifts down, the gap that drove early loss narrows and the scale flattens.

Where your weight actually went matters

Here's the part that should concern an ex-athlete most: not all weight lost is fat. During any substantial weight reduction, a portion of the loss is lean mass, including skeletal muscle. Reviews of weight-loss interventions, including pharmacologic ones, consistently show that lean mass can account for a meaningful share of total weight lost [4][5].

That matters for two reasons:

1. Muscle is metabolically active. Lose lean mass and your resting metabolic rate drops further — compounding the adaptive slowdown above.

2. Strength and function are the point. You're trying to lean out without dismantling the frame you built. Preserving lean mass is why resistance training and adequate protein are part of any serious conversation about body composition during a cut [4].

This is also why the number on the scale is a poor lie detector. Two people can be "stalled" at the same weight while one is recomposing — losing fat, holding muscle — and the other is simply under-fueled and losing both. Only looking at body composition, not body weight, tells those two stories apart.

What a provider actually reviews before calling a plateau "real"

A real clinical read on a stall is not "stay the course" and it's not an automatic switch to a different molecule. An independent provider works through the inputs that drive the energy equation before deciding anything:

  • Intake reality. Travel, client dinners, and inconsistent logging quietly shift calorie intake. Appetite suppression also fades as the body adapts. A provider looks at whether intake has genuinely held or crept up.
  • Lean mass vs. fat mass. Weight alone hides recomposition. Tools like waist circumference, and where appropriate body-composition assessment, help distinguish fat loss from muscle loss [4].
  • Activity and training. Non-exercise activity often falls during a cut, and resistance training status directly affects lean-mass retention.
  • Labs and the broader picture. Thyroid function, metabolic markers, and a review of overall health context help rule out other contributors and inform what comes next [6].
  • Tolerability and adherence. Whether the current protocol is being used consistently, and how it's being tolerated.

Only after that review does the question "should the protocol change?" make sense. Semaglutide acts on the GLP-1 pathway; tirzepatide acts on both the GIP and GLP-1 receptors [3][6]. They are different tools. Whether one fits a given person is a clinical decision an independent licensed provider makes based on that person's history, labs, and goals — never a guarantee, and never something a portal should rubber-stamp.

Two pathways, two molecules
GLP-1Semaglutide receptor targetsingle incretin pathway
GIP + GLP-1Tirzepatide receptor targetsdual incretin pathway

Source: [3] Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

What gets reviewed before a plateau is called "real"
1IntakeHas calorie intake truly held, or crept up?
2Body compositionFat vs. lean mass, waist circumference
3Activity & trainingResistance training, daily movement
4Labs & historyThyroid, metabolic markers, full context

Source: [4] Effects of weight loss on lean mass, strength, bone, and aerobic capacity, [6] Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

Why "the strongest option" is the wrong question to ask first

It's tempting to skip straight to whatever you've heard "works harder." But the more useful question is: *what is the actual bottleneck?* If lean mass is eroding and intake has drifted, switching molecules without addressing protein, training, and logging may just produce another temporary drop followed by the same adaptive flattening — at higher cost. A provider who reviews your numbers can tell you whether the limiting factor is the medication, the protocol around it, or normal metabolic adaptation that calls for a different lever entirely.

That's the difference between a medical relationship and a vending machine. The goal isn't the steepest possible line on the scale — it's losing fat while protecting the strength and metabolic capacity you want to keep for decades.

A note on compounded medications

Some semaglutide and tirzepatide products are dispensed as compounded preparations. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state. Whether any medication — compounded or brand — is appropriate is decided by an independent licensed provider.

This article is educational and is not medical advice. It cannot diagnose a plateau or tell you to start, stop, or switch any medication. Talk with a licensed provider about your specific situation.

Where Velri fits

Velri is a technology and coordination company — not a medical practice. For people working through a stall, Velri can coordinate the parts that make a real review possible: lab work through partner labs, a visit with an independent, licensed provider who can examine your intake, lean-mass picture, activity, and bloodwork, and — if that provider writes a prescription — fulfillment through an independent licensed pharmacy. Velri does not provide medical care, does not prescribe, and a prescription is never guaranteed. What it offers is the coordination so the people who can read your plateau actually have your data in front of them.